Compare PANW & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PANW | VRTX |
|---|---|---|
| Founded | 2005 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | EDP Services |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.9B | 115.7B |
| IPO Year | 2012 | 1991 |
| Metric | PANW | VRTX |
|---|---|---|
| Price | $176.64 | $470.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 38 | 27 |
| Target Price | $229.20 | ★ $512.63 |
| AVG Volume (30 Days) | ★ 6.2M | 1.5M |
| Earning Date | 02-13-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.58 | ★ 14.22 |
| Revenue | $9,556,500,000.00 | ★ $11,723,300,000.00 |
| Revenue This Year | $16.49 | $10.92 |
| Revenue Next Year | $13.21 | $8.56 |
| P/E Ratio | $111.52 | ★ $33.45 |
| Revenue Growth | ★ 15.30 | 10.33 |
| 52 Week Low | $144.15 | $362.50 |
| 52 Week High | $223.61 | $519.68 |
| Indicator | PANW | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.49 | 55.75 |
| Support Level | $171.25 | $469.50 |
| Resistance Level | $189.39 | $484.35 |
| Average True Range (ATR) | 5.32 | 11.79 |
| MACD | -0.69 | 1.26 |
| Stochastic Oscillator | 24.37 | 72.39 |
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three fourths of the Global 2000.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.